Who is sponsoring NCT03817398?

NCT03817398 is sponsored by Children's Oncology Group.

What drugs are being tested in NCT03817398?

Interventions in NCT03817398: Biospecimen Collection, Drug Withdrawn, Quality-of-Life Assessment, Questionnaire Administration, Tyrosine Kinase Inhibitor.

What condition does NCT03817398 study?

NCT03817398 studies Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive.

Is NCT03817398 still recruiting?

NCT03817398 is currently active, enrolled. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT03817398

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

Active, enrolled Phase 2 Last updated 13 April 2026

What this trial tests

Phase 2 trial testing Biospecimen Collection in Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive in 110 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

8 November 2019

Primary endpoint
30 June 2026

30 June 2026

Quick facts

Lead sponsor	Children's Oncology Group
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	110
Start date	8 November 2019
Primary completion	30 June 2026
Estimated completion	30 June 2026
Sites	173 locations across Canada, United States, Australia, Puerto Rico

Drugs / interventions tested

Biospecimen Collection — full drug profile →
Drug Withdrawn
Quality-of-Life Assessment
Questionnaire Administration
Tyrosine Kinase Inhibitor — full drug profile →

Conditions studied

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive — all drugs for Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive →

Sponsor

Children's Oncology Group — full company profile →

Who can join

Under 25, any sex, with Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies how stopping tyrosine kinase inhibitors will affect treatment-free remission in patients with chronic myeloid leukemia in chronic phase. When the level of disease is very low, it's called molecular remission. TKIs are a type of medication that help keep this level low. However, after being in molecular remission for a specific amount of time, it may not be necessary to take tyrosine kinase inhibitors. It is not yet known whether stopping tyrosine kinase inhibitors will help patients with chronic myeloid leukemia in chronic phase continue or re-achieve molecular remission.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms.
Cooper TM, Alonzo TA, Tasian SK, Kutny MA, et al · · 2023 · cited 22× · PMID 37480164 · DOI 10.1002/pbc.30584
Children's Oncology Group's 2023 blueprint for research: Diversity and health disparities.
Winestone LE, Beauchemin MP, Bona K, Kahn J, et al · · 2023 · cited 17× · PMID 37501542 · DOI 10.1002/pbc.30592
Management of Chronic Myeloid Leukemia in Children and Young Adults.
Ford M, Mauro M, Aftandilian C, Sakamoto KM, et al · · 2022 · cited 12× · PMID 35920965 · DOI 10.1007/s11899-022-00673-5
Progress in precision therapy in pediatric oncology.
O'Donohue T, Farouk Sait S, Glade Bender J. · · 2023 · cited 6× · PMID 36377257 · DOI 10.1097/mop.0000000000001198
Exploration of treatment-free remission in CML, based on molecular monitoring.
Zhang Z, Zhou X, Zhou X, Cheng Z, et al · · 2024 · cited 3× · PMID 38133525 · DOI 10.1002/cam4.6849

Verify or expand the search:

Other trials of Biospecimen Collection

Trials testing the same drug.

NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting

Other recruiting trials for Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting

Other Children's Oncology Group trials

Trials by the same sponsor.

NCT07412002 — Quality of End-of-Life Care for Children With Cancer · not yet recruiting
NCT07498465 — A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant · Phase 1 · withdrawn
NCT07022678 — Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia · Phase 3 · not yet recruiting
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT07466316 — A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Ove · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03817398 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Children's Oncology Group
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03817398.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing